CFDE Data Portal | Search OTOAP1

	Label	Description
	OTOAP1 Gene (Entity type)	ENSG00000290866 - OTOA pseudogene 1
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE222758 clofazimine U2OS 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115384 CELSR2 knockdown 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE122979 GSE122980 LCL-161 MCF-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 2 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 quinoline HT-29 Caco-2 3 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE192362 erastin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE155031 catechin SH-SY5Y 5 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

OTOAP1

ENSG00000290866 - OTOA pseudogene 1

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE222758 clofazimine U2OS 0 v 4 human up

A Gene Set from LINCS

GSE115384 CELSR2 knockdown 0 v 3 human up

A Gene Set from LINCS

GSE122979 GSE122980 LCL-161 MCF-7 2 v 0 human up

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 2 v 7 human up

A Gene Set from LINCS

GSE158632 quinoline HT-29 Caco-2 3 v 4 human dn

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 3 v 2 human up

A Gene Set from LINCS

GSE192362 erastin 1 v 0 human dn

A Gene Set from LINCS

GSE155031 catechin SH-SY5Y 5 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.